



## ARTESUNATE FOR INJECTION

### Draft proposal for *The International Pharmacopoeia*

(August 2010)

#### REVISED DRAFT FOR COMMENT

This document was provided by a quality control expert and was discussed at the recent WHO consultation on specifications for medicines and quality control laboratory issues. Previous comments received have been incorporated into this revised draft. Should you have any comments, please send these to Dr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, World Health Organization, 1211 Geneva 27, Switzerland; fax: (+41 22) 791 4730 or e-mails: [kopps@who.int](mailto:kopps@who.int) with a copy to Ms C. Mendy [mendyc@who.int](mailto:mendyc@who.int) by 11 October 2010.

**During the past few years we have moved more towards an electronic system for sending out our draft monographs for comment, for convenience and in order to speed up the process. If you do not already receive our documents electronically, please let us have your e-mail address (to [bonnyw@who.int](mailto:bonnyw@who.int)) and we will add it to our electronic mailing list.**

---

© World Health Organization 2010

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of WHO. The draft should not be displayed on any web site.

Please send any request for permission to:

Dr Sabine Kopp, Quality Assurance Programme, Medicines Quality Assurance Programme, Quality & Safety: Medicines (QSM), Department of Essential Medicines and Pharmaceutical Policies (EMP), World Health Organization, CH-1211 Geneva 27, Switzerland. Fax: (41-22) 791 4730; e-mail: [kopps@who.int](mailto:kopps@who.int).

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.

**SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/10.365**

*International Pharmacopoeia monograph on Artesunate for injection*

	<b>Date</b>
Preparation of first draft by laboratory	September 2009–April 2010
Discussion at consultation on specifications for medicines and quality control laboratory issues	10-12 May 2010
Draft monograph mailed out for comments	July 2010
Collation of comments	August 2010
Comments discussed during video-/teleconference on specifications for medicines	25 August 2010
Revised draft mailed out for comments	September 2010
Presentation to WHO Expert Committee on Specifications for Pharmaceutical Preparations	18-22 October 2010
Further action as necessary	

**ARTESUNATE FOR INJECTION**  
**Draft proposal for *The International Pharmacopoeia***  
**(August 2010)**

**Category.** Antimalarial.

**Storage.** Artesunate for injection should be kept in a hermetically closed container.

**Additional information.** Strength in the current WHO Model list of essential medicines: 60 mg.  
Strength in the current WHO Model list of essential medicines for children: 60 mg.

The reconstituted injection is a sterile solution of artesunate in 5% Sodium bicarbonate intravenous infusion. It is prepared by dissolving Artesunate for injection in the requisite amount of 5% Sodium bicarbonate intravenous infusion immediately before use. This solution is diluted further with a suitable diluent for injection in accordance with the manufacturer's instructions.

The reconstituted injection should be used immediately after preparation.

### Requirements

The powder for injection and the reconstituted injection comply with the monograph for "Parenteral preparations".

**Definition.** Artesunate for injection is a sterile powder containing Artesunate. It contains not less than 90.0% and not more than 110.0% of the amount of artesunate ( $C_{19}H_{28}O_8$ ) stated on the label.

**Manufacture.** The manufacturing process and the product packaging are designed and controlled so as to minimize the moisture content of the powder. They ensure that, if tested, the powder would comply with a water limit of not more than 5 mg/g when determined as described under 2.8 Determination of water by the Karl Fischer method, Method A.

### Identity tests

- Either test A alone or tests B, C, and D may be applied.
- A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from artesunate RS or with the *reference spectrum* of artesunate.
- B. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R5 as the coating substance and a mixture of 70 volumes of ethanol R, 30 volumes of toluene R and 1.5 volumes of ammonia (~260 g/l) TS as the mobile phase. Apply separately to the plate 1  $\mu$ l of the following two solutions in methanol R. For solution (A) dissolve a quantity of the powder to obtain a solution containing 1.0 mg of Artesunate per ml. For solution (B) use 1.0 mg of artesunate RS per ml. After removing the plate from the chromatographic chamber, allow it to dry in air or in a current of cool air. Spray with anisaldehyde/methanol TS and heat the plate to 120°C for 5 minutes. Examine the chromatogram in daylight.

The principal spot obtained with solution A corresponds in position, appearance, and intensity with that obtained with solution B.

- C. Dissolve a quantity of the powder containing 0.1 g of Artesunate in 40 ml of dehydrated ethanol R, shake, and filter. To half of the filtrate (keep the remaining filtrate for test D) add about 0.5 ml of hydroxylamine hydrochloride TS2 and 0.25 ml of sodium hydroxide (~80 g/l) TS. Heat the mixture in a water-bath to boiling, cool, add 2 drops of hydrochloric acid (~70 g/l) TS and 2 drops of ferric chloride (50 g/l) TS; a light red-violet colour is produced.
- D. Evaporate the remaining filtrate from test C on a water-bath to a volume of about 5 ml. Place a few drops of the mixture on a white porcelain dish, add one drop of vanillin/sulfuric acid TS1; a reddish-brown colour is produced.

**Bacterial endotoxins.** Carry out the test as described under 3.4 Test for bacterial endotoxins; contains not more than 2.5 IU of endotoxin per mg of artesunate.

### Related substances

Carry out the test as described under 1.14.4 High-performance liquid chromatography, using the conditions given below under Assay method A.

Use solutions (1) and (3) as described under Assay method A. For solution (4) dilute 1 ml of solution (1) to 100 ml with acetonitrile R.

Inject separately 20  $\mu$ l each of solutions (1), (3) and (4). Record the chromatograms for about 4 times the retention time of artesunate. In the chromatogram obtained with solution (3), the following peaks are eluted at the following relative retention with reference to artesunate (retention time about 9 minutes):  $\alpha$ -artenimol about 0.58,  $\beta$ -artenimol about 0.91 and impurity B (artemisinin) about 1.30. The test is not valid unless the peak-to-valley ratio ( $H_p/H_v$ ) is at least 5.0, where  $H_p$  = height above the baseline of the peak due to  $\beta$ -artenimol and  $H_v$  = the height above the baseline of the lowest point of the curve separating this peak from the peak due to artesunate. The chromatogram obtained with solution (1) may show a peak due to impurity C eluting at a relative retention of about 2.7 with reference to artesunate.

In the chromatogram obtained with solution (1):

- the combined areas of any peaks corresponding to  $\alpha$ -artenimol and  $\beta$ -artenimol (impurity A) are not greater than the area of the principal peak obtained with solution (4) (1.0%);
- the area of any peak corresponding to impurity B (artemisinin) is not greater than 0.5 times the area of the principal peak obtained with solution (4) (0.5%);
- the area of any peak corresponding to impurity C, when multiplied by a correction factor of 0.07, is not greater than 0.3 times the area of the principal peak obtained with solution (4) (0.3%);
- the area of any other peak, other than the principal peak, is not greater than 0.3 times the area of the principal peak in the chromatogram obtained with solution (4) (0.3%);
- The sum of the corrected area of any peak corresponding to impurity C and the areas of all other peaks, other than the principal peak, is not greater than twice the area of the principal peak obtained with solution (4) (2.0%). Disregard any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (4) (0.1%).

## Assay

- Either method A or method B may be applied.
- A. Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (10 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically bonded octadecylsilyl groups (3 μm).<sup>1</sup> As the mobile phase, use a mixture of 44 volumes of acetonitrile R and 56 volumes of buffer pH 3.0.

Prepare the buffer pH 3.0 by dissolving 1.36 g of potassium dihydrogen phosphate R in 900 ml of water R, adjust the pH to 3.0 with phosphoric acid (~1440 g/l) TS and dilute to 1000 ml with water R.

Prepare the following solutions in acetonitrile R. For solution (1) determine the weight of the contents of 10 containers. Transfer a quantity of the mixed contents containing about 40 mg of Artesunate, accurately weighed, to a 10-ml volumetric flask, add 7 ml and shake to dissolve. Dilute to volume and filter. For solution (2) dissolve 40 mg of artesunate RS, accurately weighed, and dilute to 10 ml. For solution (3) dissolve about 1 mg of artemimol RS, about 1 mg of artemisinin RS and about 10 mg of artesunate RS in 10 ml.

Operate with a flow rate of 1.0 ml per minute. Maintain the column temperature at 30°C and use as detector an ultraviolet spectrophotometer set at a wavelength of about 216 nm.

Inject separately 20 μl each of solutions (1), (2) and (3). Record the chromatograms for about 4 times the retention time of artesunate. In the chromatogram obtained with solution (3), the following peaks are eluted at the following relative retention with reference to artesunate (retention time about 9 minutes): α-artemimol about 0.58, β-artemimol about 0.91 and impurity B (artemisinin) about 1.30. The test is not valid unless the peak-to-valley ratio (Hp/Hv) is at least 5.0, where Hp = height above the baseline of the peak due to β-artemimol and Hv = the height above the baseline of the lowest point of the curve separating this peak from the peak due to artesunate. The chromatogram obtained with solution (1) may show a peak due to impurity C eluting at a relative retention of about 2.7 with reference to artesunate.

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2), and calculate the content of artesunate (C<sub>19</sub>H<sub>28</sub>O<sub>8</sub>) per sealed container.

- B. Determine the weight of the contents of 10 containers. Dissolve a quantity of the mixed contents containing about 0.25 g of Artesunate, accurately weighed, in 25 ml of neutralized ethanol TS and titrate with sodium hydroxide (0.05 mol/l) VS, using 2 drops of phenolphthalein/ethanol TS as indicator.

Each ml of sodium hydroxide (0.05 mol/l) VS is equivalent to 19.22 mg of C<sub>19</sub>H<sub>28</sub>O<sub>8</sub>. Calculate the content of artesunate per sealed container.

## Impurities

The impurities limited by the requirements of this monograph include those listed in the monograph for Artesunate.

\*\*\*

---

<sup>1</sup> Luna<sup>®</sup> has been found suitable.